Abstract:Epidemiology generates interest by providing plausible associations, and biochemistry and molecular biology attempt to pin down cause– effect relationships in concrete molecular terms. In this Viewpoint, we posit that coronary heart disease (CHD) and its relationship to work stress may qualify as prime example of an entity that profits from recent advances in these 2 areas of research. Relationships to hydrogen peroxide (H2O2) and ion channels provide clues for elucidating molecular pathophysiology related to psychosocial stress. The cardiovascular system is a target of psychosocial stress. The pathophysiological chain of events linking chronic psychosocial stress with cardiovascular disease (CVD) includes dysregulation in the hypothalamic–pituitary–adrenal axis and in the autonomic nervous system. Among the physiological changes are increased heart rate, increased blood pressure, energy mobilization, decreased insulin sensitivity, and endothelial dysfunction.1 These processes may ultimately result in manifest CVD. In terms of population health, the largest part of the burden of CVD is attributed to CHD. Epidemiological associations of chronic psychosocial stress at work, a core social stressor in modern life, with CHD have been repeatedly confirmed (see below). For instance, in a recent multicohort study of 90 164 individuals, the simultaneous exposure to 2 major forms of chronic psychosocial stress at work, job strain and effort–reward imbalance, revealed a 1.4-fold increase in risk for incident CHD.2 Much needs to be learned on the molecular signals involved. There is evidence linking psychosocial stress to mononuclear cell activation via nuclear factor κB.3 Fine tuning of major molecular redox switches, such as nuclear factor κB and nuclear factor E2–related factor 2/Kelch-like ECH-associated protein 1, is a central focus in current …

Disturbed Redox Homeostasis in Oxidative Distress: A Molecular Link From Chronic Psychosocial Work Stress to Coronary Heart Disease?

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

Long-term Correction of Hemophilia B Through CRISPR/Cas9 Induced Homology-Independent Targeted Integration

Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

Gene Therapy for Hemophilia B with Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro

Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Universal base editing for hemophilia B

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]